CL2020003162A1 - Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona - Google Patents
Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-dionaInfo
- Publication number
- CL2020003162A1 CL2020003162A1 CL2020003162A CL2020003162A CL2020003162A1 CL 2020003162 A1 CL2020003162 A1 CL 2020003162A1 CL 2020003162 A CL2020003162 A CL 2020003162A CL 2020003162 A CL2020003162 A CL 2020003162A CL 2020003162 A1 CL2020003162 A1 CL 2020003162A1
- Authority
- CL
- Chile
- Prior art keywords
- thiazolidine
- dione
- pyridin
- ethoxy
- hydroxyethyl
- Prior art date
Links
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398 | 2018-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003162A1 true CL2020003162A1 (es) | 2021-07-02 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003162A CL2020003162A1 (es) | 2018-06-06 | 2020-12-04 | Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210308113A1 (https=) |
| EP (1) | EP3801516A1 (https=) |
| JP (1) | JP7549344B2 (https=) |
| KR (1) | KR20210031435A (https=) |
| CN (1) | CN112512524A (https=) |
| AU (1) | AU2019283649A1 (https=) |
| BR (1) | BR112020024917A2 (https=) |
| CA (1) | CA3102407A1 (https=) |
| CL (1) | CL2020003162A1 (https=) |
| EA (1) | EA202092953A1 (https=) |
| IL (1) | IL279183A (https=) |
| MX (1) | MX2020013181A (https=) |
| SG (1) | SG11202012045UA (https=) |
| WO (1) | WO2019234689A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| MX2025013233A (es) | 2023-05-09 | 2026-02-03 | Minoryx Therapeutics S L | Formas polimorficas y formulaciones de leriglitazona |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703058A1 (en) * | 2005-11-29 | 2020-09-02 | Children's Hospital Medical Center | A method of selecting a medication for a patient |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EP3559010B1 (en) | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
-
2019
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt not_active Application Discontinuation
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en not_active Abandoned
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en not_active Ceased
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko not_active Abandoned
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112512524A (zh) | 2021-03-16 |
| WO2019234689A1 (en) | 2019-12-12 |
| BR112020024917A2 (pt) | 2021-03-09 |
| EA202092953A1 (ru) | 2021-04-12 |
| MX2020013181A (es) | 2021-02-26 |
| IL279183A (en) | 2021-01-31 |
| AU2019283649A1 (en) | 2021-01-07 |
| CA3102407A1 (en) | 2019-12-12 |
| SG11202012045UA (en) | 2021-01-28 |
| EP3801516A1 (en) | 2021-04-14 |
| KR20210031435A (ko) | 2021-03-19 |
| JP7549344B2 (ja) | 2024-09-11 |
| JP2021527045A (ja) | 2021-10-11 |
| US20210308113A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003162A1 (es) | Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona | |
| CL2021000491A1 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
| JP2013531028A5 (https=) | ||
| JP2021522247A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| EA201691997A1 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| IL282827A (en) | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| JP2015535247A5 (https=) | ||
| CY1124116T1 (el) | 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος | |
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| EA202092954A1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| MX389330B (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| US20170239242A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis | |
| EP4545142A3 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| NZ708802A (en) | Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound | |
| MX2019014306A (es) | Agente para reducir la cantidad de proteina beta amiloide. | |
| BR112022021951A2 (pt) | Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial | |
| AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
| ES2668908T3 (es) | Composición para tratar o prevenir enfermedades causadas por permeabilidad vascular, que contienen imatinib o su sal farmacéuticamente aceptable como un principio activo |